ProscaVax Vaccine Stopped Prostate Cancer Progression in 80% of Patients, Phase 1 Trial Shows
News
Six injections of OncBioMune Pharmaceuticals‘ prostate cancer vaccine ProscaVax stopped the progression of the disease in 80 percent of patients in a Phase 1 clinical trial, the company announced. The results applied to ... Read more